StockData
Crescent Biopharma, Inc. logo

Crescent Biopharma, Inc. (CBIO) stock

CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$13.04−0.46 (-3.41%)

Close on Nov 17, 2026Market cap $484.36MP/E –Yield –

Crescent Biopharma profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Crescent Biopharma's profit margin for the twelve months ending Dec 31, 2022 was -62251.7%. For fiscal 2025 it was -1419.6%, against -368994.2% the year before. The highest annual figure on record is 24.0% in fiscal 2012.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-1419.6%+367574.6
FY2023Dec 31, 2023-368994.2%−306742.5
FY2022Dec 31, 2022-62251.7%−56782.8
FY2021Dec 31, 2021-5469.0%−4966.9
FY2020Dec 31, 2020-502.1%+171443.0
FY2016Dec 31, 2016-171945.1%−171881.4
FY2015Dec 31, 2015-63.6%+10.4
FY2014Dec 31, 2014-74.0%+191.6
FY2013Dec 31, 2013-265.6%−289.6
FY2012Dec 31, 201224.0%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2026Mar 31, 2026-2240.9%+10138083.7
Q2 FY2022Jun 30, 2022-17690.1%−16337.7
Q4 FY2021Dec 31, 2021-98847.1%−89295.6
Q3 FY2021Sep 30, 2021-20023.5%−18651.2
Q2 FY2021Jun 30, 2021-10140324.6%−10140239.5
Q1 FY2021Mar 31, 2021-1352.4%+41105.4
Q4 FY2020Dec 31, 2020-9551.5%–
Q3 FY2020Sep 30, 2020-1372.3%–
Q1 FY2020Mar 31, 2020-85.1%–
Q3 FY2016Sep 30, 2016-42457.8%–

More Crescent Biopharma figures

See a number that looks wrong?